Hubertus von Baumbach, Boehringer Ingelheim chairman (Stefan Puchner/picture-alliance/dpa/AP Images)

Boehringer In­gel­heim kicks off €350M R&D cen­ter in Ger­many

In line with its ex­pec­ta­tions of snag­ging about 20 new drug ap­provals over the next sev­en years, to­day Boehringer In­gel­heim

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.